# POCI earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/POCI) · [Earnings tab](https://www.lopjlb.com/stock/POCI?tab=earnings) Updated: 2026-09-24T06:57:48 Quarters analyzed: 8 ## Cross-quarter narrative Across the series of earnings calls, Precision Optics moved from early‑stage production delays and vague guidance to record revenues and positive adjusted EBITDA by Q3 2026. Initial quarters highlighted missed revenue due to delayed cystoscope and ophthalmic programs, regulatory certification bottlenecks, and staffing shortages that strained margins. Management responded with aggressive capital spending—new clean‑room capacity, facility upgrades, and a $10 M equity raise—to scale aerospace and single‑use cystoscope lines. Demand remained strong and grew, especially in aerospace and single‑use endoscopes, while the backlog expanded. Margin pressure persisted because fixed labor costs and yield shortfalls limited the upside of higher volumes, though gross margin improved once volume and a Massachusetts tax credit lifted profitability. Regulatory and financing risks stayed present, and the Ross Optical division remained at risk. Guidance uncertainty rose as the company lifted revenue targets but warned of delayed profitability. Overall, the firm transitioned from delay‑driven revenue hits to scaling‑driven growth, yet execution risks around yield, regulatory clearance, and concentration on a few large programs continue to shape its outlook. ## Latest CallCard · Q3 Precision Optics posted record $8.7M Q3 revenue, achieved positive adjusted EBITDA, raised FY2026 guidance, but notes ongoing yield improvements and production scaling challenges. **Guidance:** raised — Management raised FY2026 revenue to $29‑31M and adjusted EBITDA to a narrower negative range, citing stronger demand and operational improvements. **Tone:** mgmt 0.7 · Q&A pressure 0.5 · divergence 0.2 Management highlighted record revenue, positive EBITDA and raised guidance, indicating optimism. ### Demand visibility Strong demand visibility from record programs and high backlog. Aerospace revenue hit $3.6M with 44% sequential growth and the single‑use cystoscope line added $2.2M; management sees a high backlog and expects continued strength into FY2027. ### Margins / costs Gross margin improved to ~24% driven by volume and tax credit. Gross margin rose to 23.6% from 10% YoY, aided by higher production volumes, better yields and a $225k refundable Massachusetts incentive credit. ### Capital allocation Raised $10M equity to fund growth and strategic investments. The oversubscribed $10M public offering will support capacity expansion, quality assurance, manufacturing engineering, supply chain upgrades and potential facility updates. ### Milestones - **Top‑tier aerospace program** [on_track]: Revenue $3.6M, yields consistently 97%. - **Single‑use cystoscope program** [at_risk]: Yields >90% but below 95% target; further process upgrades needed. - **Single‑use ophthalmic endoscope program** [new]: $3.5M follow‑on production order announced, ramping quickly. - **Ross Optical division** [on_track]: Revenue $1.3M, 65% YoY growth, contributes high variable margin. - **Low‑volume arthroscopy device** [new]: Scheduled to enter production within next 6 months. - **Upper GI scope** [new]: Planned production start within next 6 months. - **Robotic surgery articulating rigid scope** [new]: Planned production start within next 6 months. - **Unity platform program** [on_track]: One program in pipeline, discussions with four prospects. ### Fears / risks - **Yield performance**: Cystoscope yields have not yet reached the 95% target, risking margin improvement. - **Customer bottlenecks**: Aerospace client’s deployment bottlenecks forced a production slowdown, potentially affecting revenue timing. - **Market visibility**: Inability to name key customers limits market perception and may hinder sales momentum. - **New program execution**: Upcoming pipeline programs depend on successful scale‑up, posing execution risk. - **Tax credit reliance**: Future refundable credits from the Massachusetts incentive program are uncertain. - **Capital dependence**: Growth plans rely on continued investor support after the $10M raise. - **Unity platform adoption**: Uncertainty around converting Unity discussions into signed contracts. - **Geopolitical risk**: Defense/aerospace demand linked to conflicts in Ukraine and Iran could fluctuate. ### Key quotes > “Revenue was $8.7 million, a new quarterly record for Precision Optics and more than double the quarterly revenue of a year ago.” > “We've made significant progress on that line, in particular, with the yield now at over 90% consistently and continuing to grow.” — Joseph Forkey > “I'm not going to predict when the hockey stick will come. We're focused on continuing to drive programs into the engineering pipeline and continue to drive the engineering pipeline programs into production.” — Joseph Forkey ## Quarter one-liners - **2026 Q3:** Precision Optics posted record $8.7M Q3 revenue, achieved positive adjusted EBITDA, raised FY2026 guidance, but notes ongoing yield improvements and production scaling challenges. - **2026 Q2:** Precision Optics posted record Q2 revenue of $7.4M driven by aerospace and cystoscope programs, but margin pressure and a one‑quarter delay in profitability keep adjusted EBITDA negative; guidance raised revenue to $26‑28M but EBITDA outlook remains a loss. - **2026 Q1:** Precision Optics posted record Q1 2026 revenue of $6.7M, highlighted strong aerospace and cystoscope demand, noted margin pressure from rapid production ramps, and reaffirmed FY2026 guidance of >$25M revenue and positive adjusted EBITDA. - **2025 Q4:** — - **2025 Q3:** Precision Optics Q3 FY2025 revenue fell to $4.2M due to low yields and staffing constraints, but management stays upbeat citing a strong backlog, progress on the Unity platform and a $6M sales outlook for Q4. - **2025 Q2:** Precision Optics posted a strong Q2 production surge, driven by single‑use cystoscope and defense aerospace backlogs, launched the Unity platform, and outlined capacity expansions to meet growing demand, while noting regulatory and financing delays. - **2025 Q1:** Q1 FY2025 revenue met expectations but was hit by production delays; management says issues are now resolved and expects stronger Q2 results, highlighting new single‑use endoscope orders and a focus on scaling production. - **2024 Q4:** — ## Theme arcs - **Demand visibility** (improving): Strong and growing demand for aerospace and single‑use endoscopes consistently reported. - **Production scaling/yield** (deteriorating): Yield challenges and production pauses recurred, limiting revenue despite capacity expansions. - **Margin pressure** (improving): Margins pressured by fixed labor and yield issues, but gross margin rose to ~24% in Q3 2026. - **Regulatory risk** (stable): Ongoing FDA clearance delays cited each quarter. - **Guidance uncertainty** (deteriorating): Guidance shifted from vague to raised uncertainty as profitability timeline slipped. ## Guidance path 2024 Q4:vague → 2025 Q1:maintained → 2025 Q2:maintained → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:maintained → 2026 Q2:raised → 2026 Q3:raised --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/POCI`